Supernus Pharmaceuticals (SUPN) to Release Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is anticipated to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.46 per share and revenue of $155.25 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Supernus Pharmaceuticals Trading Down 4.5 %

Shares of SUPN stock opened at $33.05 on Monday. The stock has a 50 day moving average of $37.48 and a 200 day moving average of $35.38. The stock has a market cap of $1.82 billion, a P/E ratio of 30.89 and a beta of 0.90. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28.

Analyst Ratings Changes

Separately, Cantor Fitzgerald cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $57.00 to $36.00 in a research report on Wednesday, February 19th.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.